From the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P).

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P). In the upcoming issues, our editors will develop regular columns on topics ranging from billing & coding problems to legal advice and practice management tips, all of which are designed to give quick-reading, issue-solving information for today’s busy oncologists.

Along with the regular feature departments, we will also report on the broader political actions and initiatives that influence the practice of oncology. To that end, we will continue to build our working relationship with ASCO, ASH, and ACCC to deliver consensus-driven views from leading experts on issues such as the impending work-force shortage of medical and gynecological oncologists, the challenges of implementing HIT, cancer care quality initiatives, and regulatory and advocacy issues.

As always, we encourage our readers to share their thoughts, advice, or opinions about anything that appears on these pages. [Please send comments to: Ronald.Piana@cmpmedica.com.]

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.